Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

NCT07396337 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: QHRD106 Injection (Low-dose group)
DRUG: QHRD106 Injection (Middle-dose group)
DRUG: QHRD106 Injection (High-dose group)
DRUG: Placebo

Sponsor

Changzhou Qianhong Bio-pharma Co., Ltd.